Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS? — Monika Kozieł (2019) | RDL Network
Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?
This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.
Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch
Kuniaki Takahashi, Ply Chichareon, Chun Chin Chang, Mariusz Tomaniak, Rodrigo Modolo, Norihiro Kogame, H P Stoll, Christian W. Hamm, Philippe Gabríel Steg, Yoshinobu Onuma, Marco Valgimigli, P Vranckx, Stephan Windecker, Didier Carrié, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.